139 related articles for article (PubMed ID: 26017879)
1. Augmented immunoexpression of survivin correlates with parameters of aggressiveness in prostate cancer.
Danilewicz M; Stasikowska-Kanicka O; Wągrowska-Danilewicz M
Pol J Pathol; 2015 Mar; 66(1):44-8. PubMed ID: 26017879
[TBL] [Abstract][Full Text] [Related]
2. Expression of livin, survivin and caspase-3 in prostatic cancer and their clinical significance.
Gu J; Ren L; Wang X; Qu C; Zhang Y
Int J Clin Exp Pathol; 2015; 8(11):14034-9. PubMed ID: 26823716
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Value of Twist-1, E-cadherin and EZH2 in Prostate Cancer: An Immunohistochemical Study.
Abdelrahman AE; Arafa SA; Ahmed RA
Turk Patoloji Derg; 2017; 1(1):198-210. PubMed ID: 28832071
[TBL] [Abstract][Full Text] [Related]
4. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.
Khan S; Jutzy JM; Valenzuela MM; Turay D; Aspe JR; Ashok A; Mirshahidi S; Mercola D; Lilly MB; Wall NR
PLoS One; 2012; 7(10):e46737. PubMed ID: 23091600
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer.
Hua X; Yu L; Pan W; Huang X; Liao Z; Xian Q; Fang L; Shen H
Diagn Pathol; 2012 Sep; 7():127. PubMed ID: 23006319
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
7. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis of Prostate Cancer in Patients with Prostate-Specific Antigen (PSA) in the Gray Area: Construction of 2 Predictive Models.
Chen M; Ma T; Li J; Zhang HJ; Li Q; Wang JJ; Sang T; Cao CL; Cui XW
Med Sci Monit; 2021 Feb; 27():e929913. PubMed ID: 33556045
[TBL] [Abstract][Full Text] [Related]
9. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
10. Survivin and NAIP in Human Benign Prostatic Hyperplasia: Protective Role of the Association of Serenoa repens, Lycopene and Selenium from the Randomized Clinical Study.
Morgia G; Micali A; Rinaldi M; Irrera N; Marini H; Puzzolo D; Pisani A; Privitera S; Russo GI; Cimino S; Ieni A; Trichilo V; Altavilla D; Squadrito F; Minutoli L
Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28327526
[TBL] [Abstract][Full Text] [Related]
11. High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer.
Lobo J; Rodrigues Â; Antunes L; Graça I; Ramalho-Carvalho J; Vieira FQ; Martins AT; Oliveira J; Jerónimo C; Henrique R
Urol Oncol; 2018 Apr; 36(4):161.e7-161.e17. PubMed ID: 29174711
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(14):5967-70. PubMed ID: 26320481
[TBL] [Abstract][Full Text] [Related]
13. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
[TBL] [Abstract][Full Text] [Related]
15. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
16. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.
Ström P; Nordström T; Aly M; Egevad L; Grönberg H; Eklund M
Eur Urol; 2018 Aug; 74(2):204-210. PubMed ID: 29331214
[TBL] [Abstract][Full Text] [Related]
17. Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients.
Büscheck F; Sulimankhil M; Melling N; Höflmayer D; Hube-Magg C; Simon R; Göbel C; Hinsch A; Weidemann S; Izbicki JR; Jacobsen F; Mandelkow T; Blessin NC; Möller-Koop C; Lutz F; Viehweger F; Möller K; Sauter G; Lennartz M; Burandt E; Lebok P; Minner S; Bonk S; Huland H; Graefen M; Schlomm T; Fraune C
Cancer Med; 2020 Feb; 9(4):1409-1418. PubMed ID: 31893572
[TBL] [Abstract][Full Text] [Related]
18. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia.
Shariat SF; Ashfaq R; Roehrborn CG; Slawin KM; Lotan Y
J Urol; 2005 Nov; 174(5):2046-50. PubMed ID: 16217391
[TBL] [Abstract][Full Text] [Related]
19. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions.
Levakov AF; Kaćanski MM; Vucković N; Zivojinov M; Amidzić J; Sabo JI
Vojnosanit Pregl; 2015 Oct; 72(10):906-13. PubMed ID: 26665557
[TBL] [Abstract][Full Text] [Related]
20. IMPORTANCE OF APOPTOSIS MARKERS (MDM2, BCL-2 AND Bax) IN BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER.
Saker Z; Tsintsadze O; Jiqia I; Managadze L; Chkhotua A
Georgian Med News; 2015 Dec; (249):7-14. PubMed ID: 26719543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
